Update: Pharmacokinetic Considerations for Apixaban Use in End-Stage Renal Disease

Authors

Lauren K. Roller, Touro University CaliforniaFollow
Laura Baumgartner, Touro University CaliforniaFollow
William E. Dager, Touro University CaliforniaFollow

Document Type

Book Chapter

Publication Date

1-1-2017

Recommended Citation

Roller, L. K., Baumgartner, L., & Dager, W. E. (2017). Update: Pharmacokinetic considerations for apixaban use in end-stage renal disease. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells & L. M. Posey (Eds.), Pharmacotherapy: A pathophysiologic approach (10th ed.). New York, NY: McGraw-Hill Education.